Heart Institute doctors win awards for science, education, and clinical innovation

February 9, 2021

February 10, 2021, OTTAWA - The Ottawa Department of Medicine bestowed three doctors from the University of Ottawa Heart Institute with important awards in science, education, and clinical innovation. Drs. Glenn Wells, Michael Froeschl, and Calum Redpath were recognized yesterday during a virtual ceremony.

Dr. Glenn Wells is this year’s recipient of the PhD Scientist Award.

Dr. Phil Wells, Chief and Chair of the Ottawa Department of Medicine, wrote:
Dr. Glenn Wells is a leader in the basic science development of SPECT myocardial blood flow measurement. His innovation and seminal papers have led to a new technique that is about to be launched globally through an industry-sponsored study. This work has been consistently supported by peer-reviewed grants since 2006 and has been instrumental in teaching the next generation of basic scientists and clinicians. His cross collaboration with cardiac imaging, radiation oncology and nuclear medicine demonstrates his ability to bridge different scientific domains, and the totality of his research exemplifies a basic science and clinical collaboration that produces a significant impact on patient care.

Dr. Michael Froeschl is this year’s recipient of the Mentorship Award.

Dr. Phil Wells wrote:
Dr. Michael Froeschl’s infectious passion for medicine has made him renowned across the country as one of the finest educators of medical learners. He uses every patient encounter as an opportunity to teach and challenge learners, but more importantly, to understand the impact of a diagnosis on the patient’s life. His attention to, and for, cardiology fellows, particularly their well-being, through his infamous pulse checks, motivates them to be the best that they can be.

Dr. Calum Redpath is a co-recipient of this year’s Clinical Innovation Award.

Dr. Phil Wells wrote:
The collaborations Dr. Calum Redpath has set up to implement the novel technique of stereotactic non-invasive radiation therapy to ablate ventricular arrhythmias has provided many frail patients with another option to improve their quality of life. Given Dr. Redpath’s clinical expertise and judgment regarding patient care, many of his peers now seek him out for advice. The growing national and international recognition of his expertise has led to the University of Ottawa Heart Institute being only the third centre in the world to offer this therapy.

Congratulations to Drs. Wells, Froeschl, and Redpath.